Published in Hum Vaccin Immunother on January 01, 2014
Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy (2017) 0.76
The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells. Front Immunol (2017) 0.75
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer (2007) 3.99
Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol (2012) 2.94
Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity (2006) 2.62
Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest (2006) 2.53
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol (2006) 2.22
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol (2005) 1.84
Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J Immunol (2003) 1.82
FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol (2006) 1.43
Lipopeptide vaccines--yesterday, today, and tomorrow. Lancet Infect Dis (2002) 1.41
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A (2012) 1.40
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res (2009) 1.24
Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res (2011) 1.22
Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol (2000) 1.14
Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunol (2010) 1.10
Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. J Med Chem (2010) 1.06
A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine (2009) 0.98
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther (2012) 0.97
Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur J Immunol (2000) 0.96
Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One (2012) 0.92
Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res (2012) 0.91
Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway in vivo. J Leukoc Biol (2011) 0.90
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis. J Biol Chem (2003) 0.90
The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur J Immunol (2010) 0.89
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine (2006) 0.89
The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One (2010) 0.86
Advances in human papilloma virus vaccines: a patent review. Expert Opin Ther Pat (2011) 0.83
The multi-faceted roles of prostaglandin E2 in cancer-infiltrating mononuclear phagocyte biology. Immunobiology (2012) 0.83
Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors. Int J Cancer (2013) 0.83
Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol (2003) 0.83
Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol Ther (2009) 0.81
A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J Biol Chem (2011) 0.81
Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer (2014) 0.80
A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine (2008) 0.80
Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development. J Oncol (2011) 0.80
T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. J Med Virol (2011) 0.79
T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clin Vaccine Immunol (2010) 0.79
Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses. Vaccine (2008) 0.78
Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Acta Pharmacol Sin (2007) 0.77
Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity. Oncoimmunology (2012) 0.77
Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine (2011) 1.83
Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother (2005) 1.65
Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis (2012) 1.31
Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One (2012) 1.12
Immunological study of HA1 domain of hemagglutinin of influenza H5N1 virus. Biochem Biophys Res Commun (2009) 1.11
Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One (2011) 1.10
Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One (2013) 1.10
DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans. Biochem Biophys Res Commun (2008) 1.07
A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect (2008) 1.05
Production of EV71 vaccine candidates. Hum Vaccin Immunother (2012) 1.05
Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine (2008) 0.99
Human SCARB2-mediated entry and endocytosis of EV71. PLoS One (2012) 0.98
A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine (2009) 0.98
A triterpenoid methyl antcinate K isolated from Antrodia cinnamomea promotes dendritic cell activation and Th2 differentiation. Eur J Immunol (2009) 0.95
Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. J Virol Methods (2011) 0.94
A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol (2010) 0.94
Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One (2010) 0.94
Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine (2006) 0.93
Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One (2012) 0.92
Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol (2012) 0.91
Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods (2011) 0.91
Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-epsilon-caprolactone). J Biomed Mater Res B Appl Biomater (2009) 0.90
Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway in vivo. J Leukoc Biol (2011) 0.90
Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol (2013) 0.90
Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect (2009) 0.89
Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl Trop Dis (2012) 0.87
Mesenchymal stem cells promote neutrophil activation by inducing IL-17 production in CD4+ CD45RO+ T cells. Immunobiology (2012) 0.87
Rapid isolation and characterization of bacterial lipopeptides using liquid chromatography and mass spectrometry analysis. Proteomics (2011) 0.87
A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol (2013) 0.86
Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes. J Autoimmun (2010) 0.86
Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS One (2011) 0.86
A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One (2011) 0.85
Identification of novel vaccine candidates against Acinetobacter baumannii using reverse vaccinology. Hum Vaccin Immunother (2015) 0.84
Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One (2012) 0.84
Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One (2013) 0.83
Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm Res (2009) 0.83
Identification of synthetic vaccine candidates against SARS CoV infection. Biochem Biophys Res Commun (2007) 0.83
Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One (2011) 0.83
Generation and characterization of JSRV envelope transgenic mice in FVB background. Virology (2009) 0.83
Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch. Int J Nanomedicine (2012) 0.82
Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J Virol (2006) 0.82
Cancer-targeted BikDD gene therapy elicits protective antitumor immunity against lung cancer. Mol Cancer Ther (2011) 0.82
Biochemical characterizations of Escherichia coli-expressed protective antigen Ag473 of Neisseria meningitides group B. Vaccine (2010) 0.81
Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine (2009) 0.81
Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine (2011) 0.81
Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol Ther (2009) 0.81
Generating and characterizing monoclonal and polyclonal antibodies against avian H5N1 hemagglutinin protein. Biochem Biophys Res Commun (2009) 0.81
Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis (2013) 0.81
Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells. J Immunol (2014) 0.80
Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer (2014) 0.80
Immunoprotectivity of HLA-A2 CTL peptides derived from respiratory syncytial virus fusion protein in HLA-A2 transgenic mouse. PLoS One (2011) 0.80
T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. J Med Virol (2011) 0.79
T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clin Vaccine Immunol (2010) 0.79
The Development and Application of HLA Tetramers in the Detection, Characterization and Therapy of Type 1 Diabetes Mellitus. Rev Diabet Stud (2007) 0.78
Rapid and sensitive detection of cancer cells by coupling with quantum dots and immunomagnetic separation at low concentrations. Biosens Bioelectron (2011) 0.78
Increased expression of IL-21 reduces tumor growth by modulating the status of tumor-infiltrated lymphocytes. Immunobiology (2010) 0.78
Identifying conserved DR1501-restricted CD4(+) T-cell epitopes in avian H5N1 hemagglutinin proteins. Viral Immunol (2010) 0.78
Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV. Hum Vaccin Immunother (2013) 0.78
Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development. Vaccine (2005) 0.78
A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo. J Immunother (2012) 0.77
Recombinant heat shock protein 70 in combination with radiotherapy as a source of tumor antigens to improve dendritic cell immunotherapy. Front Oncol (2012) 0.77
The cross-regulatory relationship between human dendritic and regulatory T cells and its role in type 1 diabetes mellitus. Rev Diabet Stud (2007) 0.77
Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III. Microbes Infect (2013) 0.76
Tonsillar CD4+FOXP3+ T-regulatory cell dynamics in primary EBV infection. Immunol Res (2011) 0.76
Anti-ribosomal phosphoprotein autoantibody triggers interleukin-10 overproduction via phosphatidylinositol 3-kinase-dependent signalling pathways in lipopolysaccharide-activated macrophages. Immunology (2009) 0.76
Highly sensitive rare cell detection based on quantum dot probe fluorescence analysis. Anal Bioanal Chem (2009) 0.76